Immunological Disorders and Immunotherapy

OPEN ACCESS Freely available online

Commentary

A Comprehensive Guide to Antineoplastic Immunotherapies in Cancer Treatment

Oduaran Emrah*

Department of Immunology, Harvard University, Cambridge, USA

ABOUT TO STUDY

Antineoplastic immunotherapies are a class of treatments that use the body's immune system to fight cancer. These therapies represent a innovative approach to cancer treatment, focusing on boosting or manipulating the immune system to target and destroy cancer cells. Unlike traditional cancer treatments like surgery, chemotherapy, and radiation, which directly attack cancer cells or shrink tumors, antineoplastic immunotherapies work by enhancing the immune response or altering the immune system's activity to recognize and eliminate cancerous cells.

Basic concepts of antineoplastic immunotherapies

Antineoplastic immunotherapy is rooted in the idea that the immune system, which normally protects the body from infections, can also be trained to recognize cancer cells as harmful invaders. However, cancer cells often evade immune detection through various mechanisms. This ability of cancer cells to avoid immune surveillance is one of the major challenges in treating cancer. Immunotherapies aim to overcome these defenses and help the immune system target and eliminate the cancer cells.

Types of antineoplastic immunotherapies

Types of antineoplastic immunotherapies include monoclonal antibodies, checkpoint inhibitors, cytokine therapies, cancer vaccines, and CAR-T cell therapy, each designed to enhance the immune system's ability to target and destroy cancer cells more effectively.

Monoclonal antibodies

Monoclonal Antibodies (mAbs) are laboratory-made molecules designed to mimic the immune system's ability to fight off harmful pathogens such as viruses. In cancer treatment, monoclonal antibodies are engineered to specifically target proteins or antigens that are found on the surface of cancer cells. These antibodies can work in different ways. Some can directly block the activity of cancer-promoting proteins, while others can recruit immune cells to attack cancer cells or deliver toxic agents directly to cancer cells.

Examples of monoclonal antibodies used in cancer treatment include trastuzumab (Herceptin) for breast cancer and rituximab (Rituxan) for non-Hodgkin lymphoma.

Checkpoint inhibitors

One of the most exciting advancements in cancer immunotherapy is the development of checkpoint inhibitors. These drugs work by blocking checkpoint proteins, which act as brakes on the immune system. Cancer cells often exploit these proteins to turn off the immune response and avoid being attacked. Checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), prevent cancer cells from using these "brakes," allowing immune cells to recognize and attack the cancer.

These inhibitors have proven effective for various cancers, including melanoma, non-small cell lung cancer, and bladder cancer.

Cytokine therapy

Cytokines are proteins that regulate the immune system. In cytokine therapy, substances like interferons and interleukins are used to stimulate the immune system and enhance its ability to fight cancer. Interferon-alpha, for instance, is sometimes used to treat melanoma and leukemia, while Interleukin-2 (IL-2) has been used to treat kidney cancer and melanoma.

Cancer vaccines

Unlike vaccines that prevent disease, cancer vaccines are designed to treat existing cancer by stimulating the immune system to recognize and destroy cancer cells. These vaccines typically contain cancer-specific antigens, prompting the body to mount an immune response against cancer cells that carry those antigens. One well-known example is the vaccine for prostate cancer, sipuleucel-T (Provenge), which is designed to treat

Correspondence to: Oduaran Emrah, Department of Immunology, Harvard University, Cambridge, USA; E-mail: emraho@gmail.com

Received: 26-Dec-2024, Manuscript No. IDIT-24-36366; **Editor assigned:** 30-Dec-2024, PreQC No. IDIT-24-36366 (PQ); **Reviewed:** 13-Jan-2025, QC No. IDIT-24-36366; **Revised:** 26-Jul-2026, Manuscript No. IDIT-24-36366 (R); **Published:** 05-Jul-2026, DOI: 10.35248/2593-8509.26.11.266

Citation: Emrah O (2026) A Comprehensive Guide to Antineoplastic Immunotherapies in Cancer Treatment. Immunol Disord Immunother. 11:266.

Copyright: © 2026 Emrah O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

prostate cancer by boosting the body's immune system to target prostate cancer cells.

CAR-T cell therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy is an innovative treatment where a patient's own T cells are modified to express a receptor specific to cancer cells. Once modified, the T cells are expanded in the lab and infused back into the patient to enhance the immune response against cancer cells. CAR-T therapies have shown promising results in treating hematological cancers like leukemia and lymphoma, with ongoing research expanding their use to other types of cancer.

Benefits of antineoplastic immunotherapies

The primary advantage of antineoplastic immunotherapies is their ability to target cancer cells more specifically, while minimizing damage to surrounding healthy tissue. Traditional chemotherapy and radiation therapies can also harm healthy cells, leading to side effects such as fatigue, hair loss, and gastrointestinal distress. In contrast, immunotherapies generally produce fewer side effects, as they are designed to target only cancer cells.

CONCLUSION

Antineoplastic immunotherapies represent an innovative approach to cancer treatment by harnessing the body's immune system to fight cancer. With therapies like monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapy, significant progress has been made in improving outcomes for patients with various types of cancer. While challenges remain, ongoing research is continuously refining these therapies to enhance their effectiveness, reduce side effects, and expand their use to treat a broader range of cancers. As the field advances, antineoplastic immunotherapies hold great promise for improving the survival rates and quality of life for cancer patients worldwide.